Alcolase
About Alcolase
Alcolase is a Therapeutics startup based in Copenhagen, Denmark that has raised $1.7M in venture capital across 1 funding round since 2021. The company reached Seed stage in May 2026 with a $1.7M round led by Ada Ventures. Alcolase's investor base includes 4 institutional funds, with Ada Ventures leading the most recent equity round.
Alcolase is a Danish biotech startup developing an enzyme-based supplement that breaks down alcohol in the stomach before it enters the bloodstream. Using a patent-pending liposomal encapsulation platform developed with the Technical University of Denmark, the company targets ALDH2 deficiency—a genetic variant affecting approximately 540 million people globally who experience flushing, nausea, and elevated health risks when drinking alcohol. The company also operates a UK therapeutic subsidiary and is targeting initial commercial markets in Singapore and South Korea.
Alcolase Funding Rounds Timeline
1 rounds · $1.7M raised · since 2021
| Round | Date | Amount | Valuation | Lead investor | Co-investors |
|---|---|---|---|---|---|
| Seed | May 2026 | $1.7M | — | Ada Ventures | Delphinus Venture Capital, Antler, Manigoff Invest |
Investors in Alcolase
4 institutional investors across 1 rounds
Lead investors
Co-investors
Recent news about Alcolase
- FundingWhy we invested: AlcolaseMay 2026
Questions about Alcolase
How much has Alcolase raised?
Alcolase has raised $1.7M across 1 funding round since 2021.
Who are the investors of Alcolase?
Alcolase's investors include Ada Ventures, Delphinus Venture Capital, Antler, Manigoff Invest.
When was Alcolase's last funding round?
Alcolase's most recent round was a $1.7M Seed in May 2026, led by Ada Ventures.
Where is Alcolase headquartered?
Alcolase is headquartered in Copenhagen, Denmark, and was founded in 2021 by Mikkel Holstener Precht, Ib Christensen, Mads Emil Mikkelsen, Jeppe Malthe Mikkelsen.